Chi-Med Plans to Initiate Global Phase IIb Trials of its Lead Anti-Inflammatory Drug Candidate, HMPL-004, in Ulcerative Colitis Patients // Chi-Med
AIM: £45.10 (+0.35) | Nasdaq: $28.50 (-1.21)
News Archive
Previous Article   |   Next Article
Innovation Platform, RNS Announcements | 22 Nov 2007

Chi-Med Plans to Initiate Global Phase IIb Trials of its Lead Anti-Inflammatory Drug Candidate, HMPL-004, in Ulcerative Colitis Patients

1 Item
a071122